These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Lenalidomide for bortezomib-resistant multiple myeloma. Briani C; Berno T; Campagnolo M; Zambello R Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906 [No Abstract] [Full Text] [Related]
5. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936 [TBL] [Abstract][Full Text] [Related]
6. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405 [TBL] [Abstract][Full Text] [Related]
8. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score. Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516 [TBL] [Abstract][Full Text] [Related]
9. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177 [TBL] [Abstract][Full Text] [Related]
10. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. Richardson PG; Laubach JP; Schlossman RL; Mitsiades C; Anderson K J Natl Compr Canc Netw; 2010 Feb; 8 Suppl 1():S4-S12. PubMed ID: 20141673 [TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756 [TBL] [Abstract][Full Text] [Related]
12. Management of treatment-related adverse events in patients with multiple myeloma. Mateos MV Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185 [TBL] [Abstract][Full Text] [Related]